Edgewise Therapeutics (EWTX) to Release Earnings on Thursday

Key Points

• Edgewise Therapeutics (EWTX) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.42) per share.
• The company's last earnings report showed a loss of ($0.43) per share, exceeding expectations and reinforcing an overall negative earnings outlook with forecasts of ($1) EPS for the current fiscal year.
• Several institutional investors have increased their stakes in EWTX, indicating a potential growth interest as analysts maintain a consensus rating of "Moderate Buy" with an average price target of $40.55.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.02. On average, analysts expect Edgewise Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Price Performance

NASDAQ:EWTX opened at $13.52 on Thursday. Edgewise Therapeutics has a 1-year low of $10.60 and a 1-year high of $38.12. The company has a 50-day moving average of $14.09 and a 200 day moving average of $18.38. The firm has a market cap of $1.42 billion, a PE ratio of -8.72 and a beta of 0.26.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in EWTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Edgewise Therapeutics by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company's stock valued at $963,000 after acquiring an additional 2,463 shares during the period. Jones Financial Companies Lllp acquired a new stake in Edgewise Therapeutics during the 1st quarter worth about $47,000. Goldman Sachs Group Inc. grew its stake in Edgewise Therapeutics by 5.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 366,644 shares of the company's stock valued at $8,066,000 after purchasing an additional 19,753 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Edgewise Therapeutics in the first quarter valued at about $84,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Wedbush reissued an "outperform" rating and issued a $43.00 price objective on shares of Edgewise Therapeutics in a research note on Monday, April 21st. Royal Bank Of Canada restated an "outperform" rating and set a $48.00 price objective on shares of Edgewise Therapeutics in a research note on Thursday, June 5th. Guggenheim initiated coverage on Edgewise Therapeutics in a research note on Wednesday, April 30th. They issued a "buy" rating and a $41.00 target price on the stock. HC Wainwright assumed coverage on shares of Edgewise Therapeutics in a report on Monday, June 30th. They issued a "buy" rating and a $42.00 target price for the company. Finally, Raymond James Financial assumed coverage on shares of Edgewise Therapeutics in a report on Wednesday, July 30th. They issued a "strong-buy" rating and a $46.00 price target on the stock. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Edgewise Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $40.55.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.